INTANGIBLE ASSETS AND GOODWILL (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of net-book value and estimated remaining life and finite lived intangible assets

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2022:

(In thousands)	Weighted Average Remaining Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net Balance at September 30, 2022
Finite-lived intangible assets
Trade name	12.7	$	104,000	$	(18,840)	$	85,160
Customer relationships	8.3	4,000		(333)		3,667
Patents and licenses	3.1	10,942		(7,805)		3,137
Acquired developed technology (1)	7.9	860,610		(224,884)		635,726
Total finite-lived intangible assets		979,552		(251,862)		727,690
In-process research and development	n/a	1,250,000		—		1,250,000
Total intangible assets		$	2,229,552	$	(251,862)	$	1,977,690

______________

(1)The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible assets acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2021:

(In thousands)	Weighted Average Remaining Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net balance at December 31, 2021
Finite-lived intangible assets
Trade name	13.4	$	104,700	$	(13,554)	$	91,146
Customer relationships	9.6	6,700		(1,577)		5,123
Patents and licenses	3.6	10,942		(6,763)		4,179
Acquired developed technology	8.6	918,171		(176,402)		741,769
Supply agreements	5.4	2,295		(101)		2,194
Total finite-lived intangible assets		1,042,808		(198,397)		844,411
In-process research and development	n/a	1,250,000		—		1,250,000
Total intangible assets		$	2,292,808	$	(198,397)	$	2,094,411

Schedule of estimated future amortization expense, intangible assets

As of September 30, 2022, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:

(In thousands)
2022 (remaining three months)	$	22,913
2023	91,653
2024	91,319
2025	90,271
2026	89,211
Thereafter	342,323
	$	727,690

Schedule of carrying amount of goodwill

The change in the carrying amount of goodwill for the periods ended September 30, 2022 and December 31, 2021 is as follows:

(In thousands)
Balance, January 1, 2021	$	1,237,672
Thrive acquisition	948,105
Ashion acquisition	56,758
PreventionGenetics acquisition	92,637
Balance, December 31, 2021	2,335,172
OmicEra acquisition	10,809
PreventionGenetics acquisition adjustment	42
Effects of changes in foreign currency exchange rates (1)	(843)
Balance September 30, 2022	$	2,345,180

______________

(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.